PDE5 INHIBITORS
Not only sildenafil citrate (Viagra) but all of the other currently available phosphodiesterase 5 inhibitors used for erectile dysfunction may increase the risk of central serous chorioretinopathy (CSC). Two case studies of patients who developed taking PDE5 inhibitors (vardenafil and tadalafil) for erectile dysfunction showed that the condition resolved once they discontinued use of the agents but reappeared when they resumed using it and once again resolved when they stopped using it the second time. The authors of the study note that there have been previous reports of CSC in patients taking sildenafil citrate. Previous studies have also indicated a link between the use of PDE5 inhibitors and other ocular side effects, including lid oedema, hyposphagma, photophobia, mydriasis, dyschromatopsia, and nonarteritic anterior ischemic optic neuropathy. The evidence suggests CSC may be another rare PDE5 inhibitor class-specific side effect, the study’s authors said
(Aliferis et al, Ophthalmogica 2012; 227:85-89)
Latest Articles
Making Female Leadership More than a Moment
A remarkable global confluence of women in key positions.
ESCRS Talks Technology at AAO
Europe adopts technological advances, US still waiting for lenses and lasers.
Sorting Out Simultaneous Vision IOLs
The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.
Big Advantages to Small-Aperture IOLs
Small-aperture IOLs offer superior image quality with increased range of focus.
Prioritising Self-Care
Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.
Valuing Clinical Trial Design
How inclusivity and diversity can enhance scientific accuracy in research.
Knowing Iris Repair: Using Iridodiathermy in Iris Surgery
Prepare for decentred pupils and uneven irides in multiple situations.
Neuroprotectant Treatment for MacTel Type 2
Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.